India's Nationwide HPV Vaccine Drive: 3 Lakh Girls Vaccinated in Two Weeks

India has embarked on a historic nationwide Human Papillomavirus (HPV) vaccination campaign, marking a significant stride in its fight against cervical cancer, the second most common cancer among women in the country. Launched on February 28, 2026, the ambitious drive aims to vaccinate approximately 11.5 to 12 million 14-year-old girls annually across all 36 states and Union Territories. Within just two weeks of its rollout, the initiative has seen remarkable progress, with nearly 300,000 girls already receiving the vaccine, as confirmed by the Central Government on Tuesday. The vaccination campaign is offering a single dose of the quadrivalent Gardasil-4 vaccine free of cost at various government health facilities, including Ayushman Arogya Mandirs, Primary Health Centres (PHCs), Community Health Centres (CHCs), Sub-District Hospitals (SDH), District Hospitals (DHs), and Government Medical Colleges (GMCs). This voluntary vaccination requires parental consent and is tracked through the government's U-WIN digital vaccination platform, similar to the CoWIN system used during the COVID-19 pandemic. The urgency of this program is underscored by India's disproportionately high burden of cervical cancer. The country accounts for nearly a quarter of global cervical cancer cases and deaths, with over 120,000 new cases and approximately 75,000 to 80,000 fatalities reported annually. Persistent infection with high-risk HPV types, particularly 16 and 18, is responsible for the vast majority of cervical cancer cases. The Gardasil-4 vaccine protects against these critical HPV types, as well as types 6 and 11, which cause genital warts. Health authorities emphasize the vaccine's high efficacy, offering 93-100% protection against high-risk HPV strains. Several states have emerged as frontrunners in the early stages of the vaccination drive, recording the highest coverage so far. These include Madhya Pradesh, Andhra Pradesh, Tamil Nadu, Gujarat, Odisha, and Mizoram. The encouraging early uptake is attributed to increasing awareness among parents, educators, and communities regarding the benefits of early immunization, reflecting a growing recognition of preventive healthcare. Authorities anticipate that the pace of vaccination will further accelerate once school examinations conclude, allowing for broader outreach and higher participation. While this nationwide rollout is a monumental step, India's journey with HPV vaccination has seen its share of challenges. HPV vaccination was first introduced in India in 2008, but national coverage was hindered by various factors, including safety concerns (later deemed unrelated to the vaccine), misinformation, sociocultural resistance, and logistical barriers. Demonstration projects in states like Andhra Pradesh and Gujarat in 2009 faced setbacks due to these issues. However, successful, albeit limited, rollouts in Punjab and Sikkim since 2016, coupled with increasing evidence of single-dose efficacy and the prospect of an affordable indigenous vaccine, have paved the way for the current extensive program. India's indigenous HPV vaccine, Cervavac, developed by the Serum Institute of India, received approval in 2023. Although it holds promise for future widespread implementation due to its affordability and local production, the national program has initially opted for Gardasil-4. This decision is partly because Cervavac is still awaiting WHO prequalification, and studies on its single-dose efficacy are ongoing. The current vaccine supply for the national program is supported by Gavi, the Vaccine Alliance, which has secured millions of doses. This initiative aligns with the World Health Organization's (WHO) global strategy to eliminate cervical cancer by 2030, which targets 90% of girls fully vaccinated with the HPV vaccine by age 15. The Indian government's comprehensive prevention strategy extends beyond vaccination to include screening, early diagnosis, and timely treatment for cervical cancer, emphasizing a multi-faceted approach to reduce the disease burden among women. The success of this large-scale vaccination drive is crucial not only for India but also for global efforts to eradicate cervical cancer, given the country's substantial contribution to the worldwide incidence of the disease.

Frequently Asked Questions

Read Full Story on Quick Digest